Patents by Inventor Iris Lavon

Iris Lavon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acid sequences comprising NF-?B binding site within O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter region and uses thereof for the treatment of cancer and immune-related disorders
    Patent number: 8299237
    Abstract: The invention relates to nucleic acid sequences comprising NF-?B binding sites derived from the MGMT promoter region and uses thereof as decoy molecules in the treatment of cancer and immune-related disorders. More particularly, the invention relates to nucleic acid sequences as well as to modified oligonucleotides (ODNs) comprising NF-?B binding sites derived from the MGMT promoter region, and uses thereof as decoy molecules for inhibiting NF-?B enhanced expression of MGMT. The invention further relates to compositions, kits and screening methods using the NF-?B binding sites of the invention or ODNs comprising the same for treating cancer and immune related disorders.
    Type: Grant
    Filed: August 28, 2008
    Date of Patent: October 30, 2012
    Assignee: Hadasit Medical Research Services & Development Ltd.
    Inventor: Iris Lavon
  • NUCLEIC ACID SEQUENCES COMPRISING NF-kB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS
    Publication number: 20100317722
    Abstract: The invention relates to nucleic acid sequences comprising NF-?B binding sites derived from the MGMT promoter region and uses thereof as decoy molecules in the treatment of cancer and immune-related disorders. More particularly, the invention relates to nucleic acid sequences as well as to modified oligonucleotides (ODNs) comprising NF-?B binding sites derived from the MGMT promoter region, and uses thereof as decoy molecules for inhibiting NF-?B enhanced expression of MGMT. The invention further relates to compositions, kits and screening methods using the NF-?B binding sites of the invention or ODNs comprising the same for treating cancer and immune related disorders.
    Type: Application
    Filed: August 28, 2008
    Publication date: December 16, 2010
    Applicant: Hadasit Medical Research Services & Development Ltd.
    Inventor: Iris Lavon
  • Oral absorbed drugs
    Publication number: 20050004000
    Abstract: Orally nonabsorbed or poorly absorbed drugs may be converted to orally absorbed prodrug derivatives by derivatization of free functional groups selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc), 2-sulfo-9-fluorenylmethoxycarbonyl (Fms), and fluorenylmethyl (Fm).
    Type: Application
    Filed: March 26, 2002
    Publication date: January 6, 2005
    Inventors: Yoram Shechter, Matityahu Fridkin, Iris Lavon, David Brodie, Nurit Eyal, Stanley Fass, Matityahu Fridkin